vedolizumab IBD
Selected indexed studies
- Vedolizumab in IBD/PSC: A Case for Careful Vigilance? (J Crohns Colitis, 2019) [PMID:31560065]
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (Gastroenterology, 2020) [PMID:31470005]
- Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. (J Crohns Colitis, 2018) [PMID:29077833]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vedolizumab in IBD/PSC: A Case for Careful Vigilance? (2019) pubmed
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (2020) pubmed
- Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. (2018) pubmed
- Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. (2021) pubmed
- Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. (2025) pubmed
- Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. (2024) pubmed
- Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD. (2021) pubmed
- Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study. (2025) pubmed
- Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. (2022) pubmed
- Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. (2013) pubmed